Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$85.84
Change (%) Stock is Up 0.65 (0.76%)
Volume198,759
Data as of 07/21/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
07/17/14Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2014, will be released before the market opens on Thursday, July 31, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 31, 2014, at 9 a.m. ET. The call can be ac... 
Printer Friendly Version
06/26/14Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
-- Multi-study Analysis Published in Journal of Pain Research Reinforces Value of EXPAREL-Based Multimodal Analgesia Regimen -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 26, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® (bup... 
Printer Friendly Version
05/27/14Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at investor conferences during June. Mr. Stack will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 11 a.m. ET in New York. ... 
Printer Friendly Version
05/07/14Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
Expected PDUFA Date of March 5, 2015 PARSIPPANY, N.J.--(BUSINESS WIRE)--May 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL® (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAR... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com